NCT06647550View on ClinicalTrials.gov

To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2026

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

HD-6277 100mg

PO, QD

DRUG

HD-6277 50mg

PO, QD

DRUG

HD-6277 25mg

PO, QD

DRUG

Placebo

PO, QD

Trial Locations (1)

Unknown

RECRUITING

Korea University Anam Hospital, Seoul

Sponsors

Lead Sponsor

Hyundai Pharm
All Listed Sponsors
lead

Hyundai Pharm

INDUSTRY